Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Lu, Ping  [Clear All Filters]
2013
Hou H, Sun H, Lu P, Ge C, Zhang L, Li H, Zhao F, Tian H, Zhang L, Chen T, et al. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse xenograft models of human hepatocellular carcinoma. Mol Cancer Ther. 2013.
2016
Liu F, Yao Z, Jiao Q, Cao L, Feng H, Yao S, Li Y, Lu P. Inducing Specific Immune Tolerance to Prevent Type 1 Diabetes in NOD Mice. Pancreas. 2016.
Hu J-J, Yin Z, Shen W-L, Bin Xie Y-, Zhu T, Lu P, Cai Y-Z, Kong M-J, Heng BChin, Zhou Y-T, et al. Manipulating Stem Cells to Treat Calcification Pharmacological Regulation of in-situ Tissue Stem Cells Differentiation for Soft Tissue Calcification Treatment. Stem Cells. 2016.
2018
He D, Zhang J, Wu W, Yi N, He W, Lu P, Li B, Yang N, Wang D, Xue Z, et al. A novel immunodeficient rat model supports human lung cancer xenografts. FASEB J. 2018:fj201800102RR.
2019
Shi J, Lu P, Shen W, He R, Yang M-W, Fang Y, Sun Y-W, Niu N, Xue J. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Cancer Lett. 2019.
Niu N, Lu P, Yang Y, He R, Zhang L, Shi J, Wu J, Yang M, Zhang Z-G, Wang L-W, et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis. Gut. 2019.
2022
Shen X, Chen Y, Liu M, Shi J, Tang Y, Yang X, Xu D, Yao H, Lu P, Sun Y, et al. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Biochem Biophys Res Commun. 2022;615:9-16.
He R, Shi J, Xu D, Yang J, Shen Y, Jiang Y-S, Tao L, Yang M, Fu X, Yang J-Y, et al. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Cancer Lett. 2022:215693.
2024
Lu P, Xu J, Shen X, Sun J, Liu M, Niu N, Wang Q, Xue J. Spatiotemporal role of SETD2-H3K36me3 in murine pancreatic organogenesis. Cell Rep. 2024;43(2):113703.